VISTA Today Daily News Business Briefs are concise stories that bring you up to date with what’s going on around Chester County. This morning:

Fox Rothschild Creates 21 New Partners

Fox Rothschild, a national law firm with more than 600 attorneys in 21 offices coast to coast, recently elevated 21 of its attorneys to partners.

In the firm’s Exton office J. Benjamin Nevius and Gregory M. Wirt are now partners in the litigation and tax and wealth planning practice groups, respectively.

An experienced civil litigator and business counselor, J. Benjamin Nevius received his J.D. from Villanova University School of Law and his B.A. from Elizabethtown College. He has significant first-chair experience advising on everything from individuals to family-run operations and multinational corporations.

Gregory M. Wirt received his J.D. from Pennsylvania State University Dickinson School of Law and his B.A. from Gettysburg College. He is involved a broad range of areas, mainly focused on taxation and wealth planning.

Seedcopa Named Top Certified Development Corporation in the US

The Small Business Administration recently released its rankings of 504 Loan Providers for the six month period ending May 31, 2015, with Seedcopa taking the top spot.

The South Eastern Economic Development Company of Pennsylvania is one of the first Certified Development Companies formed in Pennsylvania to offer the SBA 504 program. The program assists small businesses in the purchase of fixed assets to help them grow their business.

The rankings were based on the number of days taken to get approval. The Exton based company helped facilitate regional loan projects totaling $40 million in 2014 and achieved an astonishing average of 4.9 days from submission to approval, due to its exceptional collaboration with banks and other partners.  The nationwide average was 12.5 days.

DNB Financial Corporation Reports Improved Net Income for Q2

DNB Financial Corporation has announced the second quarter net income available to common stockholders as $1.2 million, or $0.43 per diluted share.

This is an increase of $0.1 million year on year and shows improved diluted earnings up from $0.38 per share. The first half of this year is showing strong growth as net income was $2.5 million, or $0.86 per diluted share, compared to the first half of last year when it earned $2.1 million, or $0.73 per diluted share.

William S. Latoff, Chairman and CEO, said, “We are pleased with our strong second quarter results, accomplished in the face of sustained net interest margin pressure largely due to the prolonged low-interest rate environment.”

HMP Communications Launches Journal of Clinical Pathways

HMP Communications Holdings is launching a new peer-reviewed publication, the Journal of Clinical Pathways, and the Malvern Company, also announced Winston Wong, president of W-Squared Group, as the founding Editor-in-Chief.

The journal will cover a wide range of topics mostly focused on peer-reviewed educational and informational articles on original research on health economics research, clinical pathway development, as well as presenting data to demonstrate the value, using case studies, in health management.

Jeff Hennessy, HMP Communications chairman and chief executive officer, stated that the  “Journal of Clinical Pathways is the first platform designed specifically to examine the relationship between advancements in data and clinical pathways, with the ultimate goal of determining the best possible care for patients in all disease state treatment settings.”

Fibrocell Science Prices its Stock Offer at $5.80 per Share

Fibrocell Science has priced its $15 million stock offering. The Chester County cell and gene therapy company is preparing to sell 2.6 million shares of common stock at $5.80 per share. The offering is expected to close on July 27.

Fibrocellis is planning to use the expected $13.6 million in net proceeds from the stock for ongoing clinical and preclinical development of its key product candidates, azficel-T, FCX-007, and FCX-013 and for other general corporate purposes.

Earlier this week, Fibrocell and its product development partner Intrexon submitted an investigational new drug application with the Food and Drug administration to get approval to begin human testing of FCX-007.

This is Fibrocell’s lead orphan gene-therapy drug candidate for the treatment of a rare skin disorder called recessive dystrophic epidermolysis bullosa or RDEB, a disease which affects up to 2,500 people nationwide which as yet, has no cure.